Three small cap pharma stocks to buy
“The return to good form has already seen the share price triple over the past year or so, but we believe it may have further to go.� Despite the strong performance of late we believe the valuation still looks reasonable, with the shares trading on 21 times consensus forecasts for 2014, falling to 11.2 times for 2015.
SKYEPHARMA CHART
September 2014
| www.financial-spread-betting.com | 61